[Chosen One]

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer’s dementia.

“Can these subjects take these vaccinations without any anticipated side effects or adverse events? The second endpoint is the immunogenicity – can they make antibodies to tau?”

If all goes well, the next step would be a Phase 2 study to assess whether the vaccine – which has shown promising results in rodents and monkeys – is effective in human patients

https://hscnews.unm.edu/news/unm-researc...lerability.

I’m already passing thanks….